IP Library › Granted Patent US 9,913,821
Granted Patent B2
US 9,913,821 · App. 15/143,987 · Granted Mar 13, 2018

Ferric organic compounds, uses thereof and methods of making same

Inventors: David W. K. Kwok (Vancouver, CA); Nikolay Mintchev Stoynov (Vancouver, CA)
Assignee: Panion & BF Biotech Inc.
A61K31/295
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,913,821
App. No.
15/143,987
Granted
Mar 13, 2018
Kind
B2
Abstract

The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.

Claims (7)

1. A method of treating metabolic acidosis, comprising:

administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a form of ferric citrate having an intrinsic dissolution rate of at least 1.88 mg/cm 2 /min.

2. The method of claim 1 , wherein the intrinsic dissolution rate is 1.88 to 4.0 mg/cm 2 /min.

3. The method of claim 1 , wherein the intrinsic dissolution rate is 1.9 to 4.0 mg/cm 2 /min.

4. The method of claim 1 , wherein the orally administrable form is a tablet.

5. The method of claim 1 , wherein the therapeutically effective amount is about 3 to 6 grams per day.

6. The method of claim 1 , wherein the subject is a human being.

Assignments (21)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 25, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 067839/0134 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 29, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 066377/0741 →
FIFTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 4, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066205/0143 →
THIRTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 29, 2023
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063189/0065 →
TWELFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 062012/0561 →
ELEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 22, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 061297/0238 →
TENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 16, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 060529/0168 →
SECURITY INTEREST Recorded Dec 15, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058399/0055 →
SEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 12, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 057474/0770 →
SIXTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 11, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 056544/0468 →
FIFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 30, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 055776/0491 →
FOURTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 17, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054793/0455 →
THIRD AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 10, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054173/0451 →
SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 053671/0221 →
SECURITY INTEREST Recorded Apr 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052295/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: PANION & BF BIOTECH INC.
To: GLOBOASIA LLC
Reel/Frame 045255/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: KWOK, DAVID W.K.; STOYNOV, NIKOLAY MINTCHEV
To: PANION & BF BIOTECH INC.
Reel/Frame 045255/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: KWOK, DAVID W.K.; STOYNOV, NIKOLAY MINTCHEV
To: PANION & BF BIOTECH INC.
Reel/Frame 045255/0130 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 16, 2018
From: GLOBOASIA LLC
To: PANION & BF BIOTECH INC.
Reel/Frame 045255/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: KWOK, DAVID W.K.; STOYNOV, NIKOLAY MINTCHEV
To: PANION & BF BIOTECH INC.
Reel/Frame 045255/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: PANION & BF BIOTECH INC.
To: GLOBOASIA LLC
Reel/Frame 045255/0395 →
Continuity (9)
Continuation 14502774 · Sep 30, 2014
Continuation 14011357 · Aug 27, 2013
Continuation 13672900 · Nov 9, 2012
Continuation 12711679 · Feb 24, 2010
Continuation 11206981 · Aug 18, 2005
Continuation In Part PCTUS2004004646 · Feb 18, 2004
Provisional Application 60462684 · Apr 15, 2003
Provisional Application 60447690 · Feb 19, 2003
Related Publication 20170095441A1 · Apr 6, 2017